Form 8-K - Current report:
SEC Accession No. 0001193125-25-185382
Filing Date
2025-08-21
Accepted
2025-08-21 17:00:19
Documents
12
Period of Report
2025-08-21
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d928596d8k.htm   iXBRL 8-K 25293
  Complete submission text file 0001193125-25-185382.txt   139077

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kalv-20250821.xsd EX-101.SCH 2852
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20250821_lab.xml EX-101.LAB 17993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20250821_pre.xml EX-101.PRE 11262
14 EXTRACTED XBRL INSTANCE DOCUMENT d928596d8k_htm.xml XML 3646
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 251241495
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)